ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0256

Polo-Like Kinase 1 Is Upregulated in Experimental AKI and Regulates Tubular Epithelial Injury Responses

Session Information

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms

Authors

  • Park, Beamjun, Soonchunhyang University Hospital Cheonan, Cheonan-si, Chungcheongnam-do, Korea (the Republic of)
  • Kim, Dong Seop, Soonchunhyang University Hospital Cheonan, Cheonan-si, Chungcheongnam-do, Korea (the Republic of)
  • Cho, Nam-Jun, Soonchunhyang University Hospital Cheonan, Cheonan-si, Chungcheongnam-do, Korea (the Republic of)
  • Park, Samel, Soonchunhyang University Hospital Cheonan, Cheonan-si, Chungcheongnam-do, Korea (the Republic of)
  • Gil, Hyo-Wook, Soonchunhyang University Hospital Cheonan, Cheonan-si, Chungcheongnam-do, Korea (the Republic of)
Background

Acute kidney injury (AKI) is driven by tubular epithelial injury and incomplete repair, but cell-cycle regulators that connect injury responses to maladaptive repair remain incompletely defined. Polo-like kinase 1 (PLK1) is a mitotic kinase involved in cell-cycle progression and stress responses. We hypothesized that PLK1 is induced in AKI and contributes to tubular injury responses across ischemic, nephrotoxic, and hypoxic injury models.

Methods

Male C57BL/6 mice underwent bilateral renal ischemia-reperfusion injury (IRI; 23-min pedicle clamping) or cisplatin-induced AKI. Kidney injury was assessed by serum creatinine, BUN, PAS-based tubular injury scoring, and KIM-1/NGAL expression. PLK1 expression was examined by qPCR, ELISA, immunohistochemistry, and immunofluorescence with proximal tubular markers. TCMK-1 tubular epithelial cells were exposed to hypoxia-reoxygenation (H/R), and H/R-induced injury, hypoxia, cell-cycle, and senescence-related responses were compared between PLK1-suppressed and control cells.

Results

Both IRI and cisplatin AKI models showed significant renal dysfunction, tubular injury, and increased KIM-1/NGAL expression compared with controls. PLK1 expression was consistently increased at the mRNA and protein levels in injured kidneys, with predominant localization to damaged proximal tubules. In public kidney organoid and human AKI transcriptomic datasets, PLK1 was enriched in cell-cycle-associated epithelial populations, supporting its injury-linked expression pattern. In TCMK-1 cells, H/R induced PLK1 together with hypoxia and injury markers. Preliminary PLK1 suppression attenuated H/R-associated injury marker expression and altered cell-cycle/senescence-related signals, suggesting a functional role for PLK1 beyond passive injury response.

Conclusion

PLK1 is reproducibly upregulated in ischemic, nephrotoxic, and hypoxic models of AKI and localizes to injured proximal tubular epithelium. These findings identify PLK1 as a candidate mediator linking tubular injury, cell-cycle dysregulation, and maladaptive repair. Further studies will define the downstream PLK1-dependent pathway that determines adaptive versus maladaptive tubular recovery after AKI.

Acknowledgment

This research was supported by Individual Basic Research Program (Mid-Career Research – Creative Research Type), the National Research Foundation of Korea(NRF) funded by the Ministry of Education(RS-20250988).

Funding

  • Government Support – Non-U.S.